Condition: Non-hematologic Cancer · Sponsor: Sequenom, Inc.
This specimen collection is designed to obtain whole blood and tumor tissue from subjects diagnosed with cancer for the purpose of the development of a noninvasive liquid biopsy assay using next generation sequencing (NGS).
This description comes directly from the study's public registry record.
Graham McLennan · (858) 202-9162 · gmclennan@sequenom.com
Always discuss trial participation with your own doctor first.
| Idaho Urology | Boise, Idaho, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02586389